Literature DB >> 22193230

Melatonin levels in premenopausal women with fibromyalgia syndrome.

Kazim Senel1, Fatih Baygutalp, Tuba Baykal, Akin Erdal, Mahir Ugur.   

Abstract

The fibromyalgia syndrome (FMS) is a chronic, widespread pain disorder of unknown etiology. It has been suggest that familial component, environmental factors, endocrine and neurotransmitter alterations, and psychological factors may contribute to the development of FMS. The role of melatonin in FMS is unclear. Some studies describe a lower nocturnal peak and a decreased secretion of melatonin in women with FMS when compared with healthy matched controls. The aim of the present study was to determine the possible role of melatonin in FMS patients. We examined the characteristics and levels of melatonin in 25 consecutive premenopausal women with FMS. Serum blood samples were collected from 25 patients and 20 the age and gender matched healthy controls. Melatonin levels were measured by enzyme-linked immunosorbent assay. Then, the results were compared with those from healthy subjects. Serum melatonin levels of FMS patients were not statistically different from those of controls (P > 0.05). No association was observed between melatonin levels of patients with FMS and disease duration, sleep disturbances, fatigue, and pain scores. Our results demonstrate that melatonin levels were similar in patients with FMS and healthy controls. Further studies are needed to determine the possible role of melatonin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22193230     DOI: 10.1007/s00296-011-2315-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  9 in total

1.  Melatonin therapy in fibromyalgia.

Authors:  D Acuna-Castroviejo; G Escames; R J Reiter
Journal:  J Pineal Res       Date:  2006-01       Impact factor: 13.007

2.  Fibromyalgia and melatonin: are they related?

Authors:  S M Webb
Journal:  Clin Endocrinol (Oxf)       Date:  1998-08       Impact factor: 3.478

3.  Circadian rhythms of dopamine and dihydroxyphenyl acetic acid in the mouse striatum: effects of pinealectomy and of melatonin treatment.

Authors:  Hoda Khaldy; Josefa León; Germaine Escames; Leila Bikjdaouene; Joaquín José García; Darío Acuña-Castroviejo
Journal:  Neuroendocrinology       Date:  2002-03       Impact factor: 4.914

4.  Normal melatonin levels in patients with fibromyalgia syndrome.

Authors:  J Press; M Phillip; L Neumann; R Barak; Y Segev; M Abu-Shakra; D Buskila
Journal:  J Rheumatol       Date:  1998-03       Impact factor: 4.666

5.  Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages.

Authors:  Juan C Mayo; Rosa M Sainz; Dun-Xian Tan; Rüdiger Hardeland; Josefa Leon; Carmen Rodriguez; Russel J Reiter
Journal:  J Neuroimmunol       Date:  2005-08       Impact factor: 3.478

Review 6.  Melatonin: therapeutic and clinical utilization.

Authors:  A Altun; B Ugur-Altun
Journal:  Int J Clin Pract       Date:  2007-02-13       Impact factor: 2.503

7.  Fibromyalgia--a syndrome associated with decreased nocturnal melatonin secretion.

Authors:  J Wikner; U Hirsch; L Wetterberg; S Röjdmark
Journal:  Clin Endocrinol (Oxf)       Date:  1998-08       Impact factor: 3.478

8.  Serum melatonin levels in ankylosing spondilitis: correlation with disease activity.

Authors:  Kazim Senel; Tuba Baykal; Meltem Alkan Melikoglu; Akin Erdal; Saliha Karatay; Akar Karakoc; Mahir Ugur
Journal:  Rheumatol Int       Date:  2009-10-24       Impact factor: 2.631

Review 9.  Fibromyalgia pain: do we know the source?

Authors:  Roland Staud
Journal:  Curr Opin Rheumatol       Date:  2004-03       Impact factor: 5.006

  9 in total
  1 in total

Review 1.  Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.

Authors:  Domenico De Berardis; Michele Fornaro; Nicola Serroni; Daniela Campanella; Gabriella Rapini; Luigi Olivieri; Venkataramanujam Srinivasan; Felice Iasevoli; Carmine Tomasetti; Andrea De Bartolomeis; Alessandro Valchera; Giampaolo Perna; Monica Mazza; Marco Di Nicola; Giovanni Martinotti; Massimo Di Giannantonio
Journal:  Int J Mol Sci       Date:  2015-01-05       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.